Activity of linezolid and high-dose daptomycin, alone or in combination, in an in vitro model of Staphylococcus aureus biofilm

被引:60
作者
Parra-Ruiz, Jorge [1 ]
Bravo-Molina, Alejandra [2 ]
Pena-Monje, Alejandro [1 ]
Hernandez-Quero, Jose [1 ]
机构
[1] HU San Cecilio, Serv Enfermedades Infecciosas, Granada, Spain
[2] HU San Cecilio, Serv Angiol & Cirugia Vasc, Granada, Spain
关键词
MRSA; S; aureus; PK; PD; RIFAMPICIN; PHARMACOKINETICS; VANCOMYCIN; RESISTANCE; EFFICACY; THERAPY; BLOOD; MRSA;
D O I
10.1093/jac/dks272
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The aim of the study was to assess the in vitro activity of linezolid and daptomycin, alone and in combination, against three Staphylococcus aureus isolates using a pharmacokinetic/pharmacodynamic (PK/PD) model of biofilm for 3 days. One non-clinical methicillin-resistant S. aureus isolate (N315) and two clinical methicillin-resistant S. aureus isolates were evaluated. Simulated regimens included high-dose daptomycin (10 mg/kg once daily) and linezolid (600 mg twice daily), alone and in combination. Against all three strains, neither linezolid nor daptomycin alone was bactericidal against biofilm-embedded bacteria (BB). Against planktonic bacteria (PB) only daptomycin was bactericidal. In contrast, the combination of linezolid and daptomycin demonstrated greater activity than either of the two agents alone, being bactericidal against both PB and BB, almost reaching the limit of detection at 72 h. In this in vitro PK/PD model of mature biofilms, a combination of linezolid plus daptomycin was more effective than each agent alone, representing another potential option to treat S. aureus biofilm-associated infections.
引用
收藏
页码:2682 / 2685
页数:4
相关论文
共 23 条
[1]   Linezolid Alone or Combined with Rifampin against Methicillin-Resistant Staphylococcus aureus in Experimental Foreign-Body Infection [J].
Baldoni, Daniela ;
Haschke, Manuel ;
Rajacic, Zarko ;
Zimmerli, Werner ;
Trampuz, Andrej .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (03) :1142-1148
[2]   Prosthetic joint infection: Recent developments in diagnosis and management [J].
Cataldo, Maria Adriana ;
Petrosillo, Nicola ;
Cipriani, Michela ;
Cauda, Roberto ;
Tacconelli, Evelina .
JOURNAL OF INFECTION, 2010, 61 (06) :443-448
[3]   The Calgary Biofilm Device: New technology for rapid determination of antibiotic susceptibilities of bacterial biofilms [J].
Ceri, H ;
Olson, ME ;
Stremick, C ;
Read, RR ;
Morck, D ;
Buret, A .
JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (06) :1771-1776
[4]  
Clinical and Laboratory Standards Institute, 2009, M07A8 CLSI
[5]   Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention [J].
El Helou, O. C. ;
Berbari, E. F. ;
Lahr, B. D. ;
Eckel-Passow, J. E. ;
Razonable, R. R. ;
Sia, I. G. ;
Virk, A. ;
Walker, R. C. ;
Steckelberg, J. M. ;
Wilson, W. R. ;
Hanssen, A. D. ;
Osmon, D. R. .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2010, 29 (08) :961-967
[6]   Rifampin Combination Therapy for Nonmycobacterial Infections [J].
Forrest, Graeme N. ;
Tamura, Kimberly .
CLINICAL MICROBIOLOGY REVIEWS, 2010, 23 (01) :14-34
[7]   Efficacy of clarithromycin plus vancomycin in mice with implant-related infection caused by biofilm-forming Staphylococcus aureus [J].
Fujimura, Shigeru ;
Sato, Tetsuro ;
Kikuchi, Toshiaki ;
Zaini, Jamal ;
Gomi, Kazunori ;
Watanabe, Akira .
JOURNAL OF ORTHOPAEDIC SCIENCE, 2009, 14 (05) :658-661
[8]   Linezolid: An oxazolidinone antimicrobial agent [J].
Fung, HB ;
Kirschenbaum, HL ;
Ojofeitimi, BO .
CLINICAL THERAPEUTICS, 2001, 23 (03) :356-391
[9]   Telavancin:: in vitro activity against staphylococci in a biofilm model [J].
Gander, S ;
Kinnaird, A ;
Finch, R .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 56 (02) :337-343
[10]  
Guay DRP, 2001, CLIN THER, V23, P566